Rankings / Longevity — Senolytics & Polyphenols
Pterostilbene
Longevity · Polyphenol
Tier C-
Bottom line
Read Off Label grades Pterostilbene as C- (4.5/10) based on weak-preclinical evidence, low-med / varies benefit magnitude, and a low-med-risk safety profile.
Paired with NR in EH301 trial — modest ALS functional improvement.
Typical use: 50-250 mg/day — OTC.
What this is
Paired with NR in EH301 trial — modest ALS functional improvement. Better absorbed than resveratrol in theory but limited direct head-to-head human data. Often combined with nicotinamide riboside (e.g., Basis, Niagen+).
Mechanism
Dimethylated resveratrol analog; better oral bioavailability (~80% vs 1%); SIRT1 activator; AMPK activator; anti-inflammatory
Dose & route
50-250 mg/day
Citations
- https://pubmed.ncbi.nlm.nih.gov/28871885/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC5118535/
- https://pubmed.ncbi.nlm.nih.gov/31728050/
- https://pubmed.ncbi.nlm.nih.gov/41693952/
- https://pubmed.ncbi.nlm.nih.gov/41470833/
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does Pterostilbene work?
- Read Off Label rates the evidence for Pterostilbene as Weak-Preclinical and the benefit magnitude as low-med / varies, producing an overall grade of C- (4.5/10). Paired with NR in EH301 trial — modest ALS functional improvement.
- Is Pterostilbene safe?
- Pterostilbene has a low-med risk profile in published human data. Legal status: OTC. This is not medical advice — see the disclaimer.
- What is the typical dose for Pterostilbene?
- 50-250 mg/day
- How does Pterostilbene work?
- Dimethylated resveratrol analog; better oral bioavailability (~80% vs 1%); SIRT1 activator; AMPK activator; anti-inflammatory
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.